Literature DB >> 26343033

[Ultrasmall nanoparticles for radiotherapy: AGuIX].

F Lux1, A Detappe2, S Dufort3, L Sancey1, C Louis3, S Carme2, O Tillement4.   

Abstract

Since twenty years, many nanoparticles based on high atomic number elements have been developed as radiosensitizers. The design of these nanoparticles is limited by the classical rules associated with the development of nanoparticles for oncology and by the specific ones associated to radiosensitizers, which aim to increase the effect of the dose in the tumor area and to spare the health tissues. For this application, systemic administration of nanodrugs is possible. This paper will discuss the development of AGuIX nanoparticles and will emphasize on this example the critical points for the development of a nanodrug for this application. AGuIX nanoparticles display hydrodynamic diameters of a few nanometers and are composed of polysiloxane and gadolinium chelates. This particle has been used in many preclinical studies and is evaluated for a further phase I clinical trial. Finally, in addition to its high radiosensitizing potential, AGuIX display MRI functionality and can be used as theranostic nanodrug for personalized medicine.
Copyright © 2015 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  IRM; MRI; Nanoparticles; Nanoparticules; Radiotherapy; Radiothérapie; Theranostic; Théranostique

Mesh:

Substances:

Year:  2015        PMID: 26343033     DOI: 10.1016/j.canrad.2015.05.019

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  3 in total

Review 1.  Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review.

Authors:  Sophie Bockel; Sophie Espenel; Roger Sun; Isabelle Dumas; Sébastien Gouy; Philippe Morice; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2021-03-11       Impact factor: 6.639

2.  AGuIX nanoparticles enhance ionizing radiation-induced ferroptosis on tumor cells by targeting the NRF2-GPX4 signaling pathway.

Authors:  Hao Sun; Hui Cai; Chang Xu; Hezheng Zhai; François Lux; Yi Xie; Li Feng; Liqing Du; Yang Liu; Xiaohui Sun; Qin Wang; Huijuan Song; Ningning He; Manman Zhang; Kaihua Ji; Jinhan Wang; Yeqing Gu; Géraldine Leduc; Tristan Doussineau; Yan Wang; Qiang Liu; Olivier Tillement
Journal:  J Nanobiotechnology       Date:  2022-10-14       Impact factor: 9.429

Review 3.  AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine.

Authors:  François Lux; Vu Long Tran; Eloïse Thomas; Sandrine Dufort; Fabien Rossetti; Matteo Martini; Charles Truillet; Tristan Doussineau; Guillaume Bort; Franck Denat; Frédéric Boschetti; Goran Angelovski; Alexandre Detappe; Yannick Crémillieux; Nathalie Mignet; Bich-Thuy Doan; Benoit Larrat; Sébastien Meriaux; Emmanuel Barbier; Stéphane Roux; Peter Fries; Andreas Müller; Marie-Caline Abadjian; Carolyn Anderson; Emmanuelle Canet-Soulas; Penelope Bouziotis; Muriel Barberi-Heyob; Céline Frochot; Camille Verry; Jacques Balosso; Michael Evans; Jacqueline Sidi-Boumedine; Marc Janier; Karl Butterworth; Stephen McMahon; Kevin Prise; Marie-Thérèse Aloy; Dominique Ardail; Claire Rodriguez-Lafrasse; Erika Porcel; Sandrine Lacombe; Ross Berbeco; Awatef Allouch; Jean-Luc Perfettini; Cyrus Chargari; Eric Deutsch; Géraldine Le Duc; Olivier Tillement
Journal:  Br J Radiol       Date:  2018-09-18       Impact factor: 3.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.